An Open-Label, FIH Study Evaluating the Safety, Tolerability, and Efficacy of VCTX211 Combination Product in Subjects With T1D
Launched by CRISPR THERAPEUTICS AG · Sep 30, 2022
Trial Information
Current as of June 05, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new treatment called VCTX211, which is designed to help people with Type 1 Diabetes (T1D). The main goals of the study are to see how safe the treatment is, how well it works, and how well patients can tolerate it. The trial is currently recruiting participants and is open to anyone aged 18 and older who has been diagnosed with T1D for at least 5 years and has been on a stable diabetes treatment for the last 3 months.
To participate in the trial, individuals must not have had any organ transplants, must not have experienced severe low blood sugar episodes recently, and should not be on certain medications that weaken the immune system. If eligible, participants will have the chance to try this new treatment and will be closely monitored by medical professionals throughout the study. This trial is an important step in exploring new options for managing Type 1 Diabetes, and participants will be contributing to valuable research that could benefit others in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Diagnosis of T1D for a minimum of 5 years
- • Stable diabetes regimen for at least 3 months prior to enrollment.
- Exclusion Criteria:
- • Medical history of islet cell, kidney, and/or pancreas transplant
- • Occurrence of 2 or more severe, unexplained hypoglycemic events within 6 months prior to enrollment
- • Known causes of diabetes other than T1D
- • Immunosuppressant therapy in the previous 30 days and/or requirements for chronic immunosuppressive therapy during the study
- • Prior treatment with gene therapy or edited product
About Crispr Therapeutics Ag
Crispr Therapeutics AG is a pioneering biotechnology company focused on developing transformative gene-based medicines using its proprietary CRISPR/Cas9 gene-editing technology. Founded in 2013 and headquartered in Zug, Switzerland, the company is dedicated to advancing the field of genetic medicine to address serious diseases, including genetic disorders, cancer, and autoimmune diseases. With a robust pipeline of clinical and preclinical programs, Crispr Therapeutics collaborates with leading institutions and industry partners to harness the potential of gene editing for innovative therapeutic solutions, aiming to improve patient outcomes and redefine the standards of care in modern medicine.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Edmonton, Alberta, Canada
Vancouver, British Columbia, Canada
Patients applied
Trial Officials
Manasi Jaiman, MD, MPH
Study Director
ViaCyte
Sandeep Soni, MD
Study Director
CRISPR Therapeutics
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials